The Phase II trial CheckMate 568 [80] was designed to evaluate the efficacy and safety of first-line treatment with nivolumab in combination with low-dose ipilimumab in advanced NSCLC patients, and to investigate the correlation between treatment efficacy with PD-L1 expression and tumor mutational burden (TMB). The gene discussed is CD274; the disease is neoplasm.